Clinical trial
A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or…
NCT00051597 · Seagen Inc., Industry · Completed
Key facts
| NCT number | NCT00051597 |
|---|---|
| Title | A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies |
| Official title | A Phase I/II Multi-Dose Study of SGN-30 in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies |
| Lead sponsor | Seagen Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Hodgkin Disease, Lymphoma, Large-Cell, Sarcoma, Kaposi, T-Cell, Cutaneous, B-Cell |
| Intervention type | Drug |
| Interventions | SGN-30 (monoclonal antibody) |
| Enrollment | 70 |
| Completion | Aug 1, 2003 |
| First posted | Jan 15, 2003 |
| Last update posted | Oct 12, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: